Bank Of New York Mellon Corp Aerovate Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	SELL	$17.68 - $29.57 $157,245 - $262,995	-8,894 Reduced 24.33%	27,664 $818 Million
Q4 2023 Jan 29, 2024	BUY	$9.58 - $24.25 $87,618 - $221,790	9,146 Added 33.36%	36,558 $827 Million
Q3 2023 Oct 24, 2023	BUY	$12.9 - $18.88 $2,322 - $3,398	180 Added 0.66%	27,412 $372 Million
Q2 2023 Aug 03, 2023	SELL	$15.63 - $22.01 $8,799 - $12,391	-563 Reduced 2.03%	27,232 $467 Million
Q1 2023 May 09, 2023	BUY	$19.17 - $27.7 $532,830 - $769,921	27,795 New	27,795 $561 Million
Q4 2022 Feb 14, 2023	BUY	$15.92 - $30.52 $447,256 - $857,428	28,094 New	28,094 $823,000
Q3 2022 Nov 14, 2022	BUY	$14.77 - $25.79 $36,614 - $63,933	2,479 Added 9.89%	27,546 $457,000
Q2 2022 Aug 15, 2022	SELL	$10.8 - $16.91 $58,536 - $91,652	-5,420 Reduced 17.78%	25,067 $392,000
Q1 2022 May 11, 2022	BUY	$8.25 - $18.33 $55,060 - $122,334	6,674 Added 28.03%	30,487 $559,000
Q4 2021 Feb 11, 2022	BUY	$9.14 - $21.54 $18,481 - $43,553	2,022 Added 9.28%	23,813 $281,000
Q3 2021 Nov 12, 2021	BUY	$11.76 - $22.49 $256,262 - $490,079	21,791 New	21,791 $457,000

28.4M

116K

26.6K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $63.6M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.